Idrees Muhammad Mubashar, Saeed Khadija, Shahid Muhammad Akbar, Akhtar Muhammad, Qammar Khadija, Hassan Javariya, Khaliq Tayyaba, Saeed Ali
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan 60800, Punjab, Pakistan.
Department of Medical Laboratory Technology, The Islamia University of Bahawalpur, Bahawalpur 63100, Punjab, Pakistan.
Biomedicines. 2023 Mar 13;11(3):878. doi: 10.3390/biomedicines11030878.
Methicillin-resistant (MRSA) is a clinically prevalent bacterium and is resistant to many drugs. Genetic factors such as genes are considered to be responsible for this resistance. Recently, Cassette Chromosome () element mutations produced , a new genetic variant that encodes a transpeptidase enzyme (63% similarity with -encoded PBP2a). This cross-sectional study was conducted to establish the prevalence of the and genes among phenotypically identified MRSA and their effectiveness against different antibiotics in clinical specimens. The prevalence of was 10.2% ( = 102) in the total number of clinical specimens collected ( = 1000). However, the prevalence of MRSA was 6.3% ( = 63) of the total samples collected, while it was 61.8% among total isolates. genes were confirmed in 96.8% ( = 61) isolates of MRSA, while 3.2% ( = 2) were found to be negative for genes. The combination of and was detected in 57.1% ( = 36) of the MRSA isolates. The prevalence of lone was 31.8% ( = 20) and that of lone was 7.9% ( = 5) among all the MRSA samples. Penicillin and amoxicillin/clavulanic acid were the most resistant antibiotics followed by norfloxacin (91.2%), levofloxacin (87.1%), ciprofloxacin (83.9%), azithromycin (78.6%), erythromycin (77.4%), moxifloxacin (69.8%), and sulfamethoxazole/trimethoprim (54.9%) On the other hand, vancomycin and teicoplanin (98.4%) were more effective drugs against MRSA followed by linezolid (96.7%), clindamycin (84.6%), chloramphenicol (83.7%), fusidic acid (70.6%), gentamicin (67.7%), and tetracycline (56.8%). In conclusion, a significant prevalence of and has been found among MRSA isolated from clinical specimens, which is likely responsible for antibiotic resistance in MRSA in our clinical settings. However, vancomycin, teicoplanin, and linezolid were found the top three most effective drugs against MRSA in our clinical settings. Thus, MRSA endemics in local areas require routine molecular and epidemiological investigation.
耐甲氧西林金黄色葡萄球菌(MRSA)是一种临床常见细菌,对多种药物耐药。基因等遗传因素被认为是导致这种耐药性的原因。最近,盒式染色体(CC)元件突变产生了mecC,这是一种新的基因变体,编码一种转肽酶(与mecA编码的PBP2a有63%的相似性)。本横断面研究旨在确定表型鉴定的MRSA中mecA和mecC基因的流行情况及其对临床标本中不同抗生素的耐药性。在所收集的临床标本总数(n = 1000)中,mecC的流行率为10.2%(n = 102)。然而,MRSA在所收集的总样本中的流行率为6.3%(n = 63),而在所有金黄色葡萄球菌分离株中的流行率为61.8%。在96.8%(n = 61)的MRSA分离株中检测到mecA基因,而3.2%(n = 2)的mecA基因检测为阴性。在57.1%(n = 36)的MRSA分离株中检测到mecA和mecC的组合。在所有MRSA样本中,单独mecC的流行率为31.8%(n = 20),单独mecA的流行率为7.9%(n = 5)。青霉素和阿莫西林/克拉维酸是耐药性最强的抗生素,其次是诺氟沙星(91.2%)、左氧氟沙星(87.1%)、环丙沙星(83.9%)、阿奇霉素(78.6%)、红霉素(77.4%)、莫西沙星(69.8%)和磺胺甲恶唑/甲氧苄啶(54.9%)。另一方面,万古霉素和替考拉宁(98.4%)是对抗MRSA更有效的药物,其次是利奈唑胺(96.7%)、克林霉素(84.6%)、氯霉素(83.7%)、夫西地酸(70.6%)、庆大霉素(67.7%)和四环素(56.8%)。总之,从临床标本中分离出的MRSA中,mecA和mecC有显著流行,这可能是我们临床环境中MRSA产生抗生素耐药性的原因。然而,在我们的临床环境中,万古霉素、替考拉宁和利奈唑胺被发现是对抗MRSA最有效的三种药物。因此,当地的MRSA流行情况需要进行常规的分子和流行病学调查。